Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
- To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging progression-free survival (PFS) in advanced ALK-positive NSCLC patients who are treatment naïve.
Inclusion criteria
- Advanced ALK positive non small cell lung cancer